_
Rehovot's Weizmann Institute’s Commercial Arm has plenty of innovative drugs in the pipeline
Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science, Israel’s leading center of research and graduate education. The Institute’s activities range across the spectrum of contemporary science. Yeda holds an exclusive agreement with the Institute for the marketing and commercialization of new developments emerging from the Institute’s laboratories.
In the pipeline:
Diapep 277
Peptide vaccine for the treatment of type 1 diabetes, acts to protect the insulin producing beta-cells from auto immune destruction. DiaPep277 is licensed to Develogen (formerly Peptor Ltd.) and has successfully completed phase II clinical development. A pivotal phase III trial for the treatment of type 1 diabetes commenced in September 2005.
Hepex B
Combination of two fully human monoclonal antibodies against the hepatitis B virus surface antigen, HBsAg. It is being developed to prevent hepatitis B, known as HBV, re-infection following a liver transplant. Licensed to XTL Biopharmaceuticals Ltd. (XTLbio). HepeX-B is currently in a Phase IIb trial in liver transplant patients.
ProCord
Cell- based therapy for spinal cord injury. Licensed to Proneuron, currently in phase II/III (fast track) clinical trials.
Edratide
CDR1-based peptide derived from a human anti-DNA antibody. Currently in phase I clinical trials for systemic lupus erythematosus (SLE), licensed to Teva Pharmaceuticals Ltd.
OxSodrol
Recombinant copper-zinc Superoxide dismutase - (CuZnSOD) for prevention of pulmonary damage in neonates, licensed to Bio-Technology General, Inc., a subsidiary of Ferring Inc. The company completed a phase II clinical trial on use of CuZnSOD in treatment of bronchopulmonary dysplasia.
Onercept
Recombinant human tumor necrosis factor-binding protein-1 (r-TBP-1), licensed to Inter-Lab Ltd., a Serono company. Currently in phase I clinical trials for endometriosis.
Tadekinig
Recombinant IL-18 binding protein (r-IL-18 BP), currently in phase I clinical trials for Crohn’s disease and rheumatoid arthritis, licensed to Serono.
XTL-6865
Combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. It is being developed to prevent hepatitis C, known as HCV, re-infection following a liver transplant and for the treatment of chronic HCV. Licensed to XTL Biopharmaceuticals Ltd. (XTLbio). Currently in phase Ia/Ib clinical trials.
Tookad
Pd-bacteriophephorbide photosensitizer (WST09) is a novel light-responsive drug, based on chlorophyll that has been shown to kill tumor tissues by destroying their blood supply after local illumination with a diode laser (763 nm). It then rapidly clears from the body. Licensed to Steba Biotech. This photodynamic therapy is currently in phase I/II clinical trials as second line therapy for prostate cancer patients who had had failed radiation therapy.
Source: Van Nadel. Weizmann Institute’s Yeda has plenty of innovative drugs in the pipeline. (24 September 2006) [FullText][Cached Version]
In the pipeline:
Diapep 277
Peptide vaccine for the treatment of type 1 diabetes, acts to protect the insulin producing beta-cells from auto immune destruction. DiaPep277 is licensed to Develogen (formerly Peptor Ltd.) and has successfully completed phase II clinical development. A pivotal phase III trial for the treatment of type 1 diabetes commenced in September 2005.
Hepex B
Combination of two fully human monoclonal antibodies against the hepatitis B virus surface antigen, HBsAg. It is being developed to prevent hepatitis B, known as HBV, re-infection following a liver transplant. Licensed to XTL Biopharmaceuticals Ltd. (XTLbio). HepeX-B is currently in a Phase IIb trial in liver transplant patients.
ProCord
Cell- based therapy for spinal cord injury. Licensed to Proneuron, currently in phase II/III (fast track) clinical trials.
Edratide
CDR1-based peptide derived from a human anti-DNA antibody. Currently in phase I clinical trials for systemic lupus erythematosus (SLE), licensed to Teva Pharmaceuticals Ltd.
OxSodrol
Recombinant copper-zinc Superoxide dismutase - (CuZnSOD) for prevention of pulmonary damage in neonates, licensed to Bio-Technology General, Inc., a subsidiary of Ferring Inc. The company completed a phase II clinical trial on use of CuZnSOD in treatment of bronchopulmonary dysplasia.
Onercept
Recombinant human tumor necrosis factor-binding protein-1 (r-TBP-1), licensed to Inter-Lab Ltd., a Serono company. Currently in phase I clinical trials for endometriosis.
Tadekinig
Recombinant IL-18 binding protein (r-IL-18 BP), currently in phase I clinical trials for Crohn’s disease and rheumatoid arthritis, licensed to Serono.
XTL-6865
Combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. It is being developed to prevent hepatitis C, known as HCV, re-infection following a liver transplant and for the treatment of chronic HCV. Licensed to XTL Biopharmaceuticals Ltd. (XTLbio). Currently in phase Ia/Ib clinical trials.
Tookad
Pd-bacteriophephorbide photosensitizer (WST09) is a novel light-responsive drug, based on chlorophyll that has been shown to kill tumor tissues by destroying their blood supply after local illumination with a diode laser (763 nm). It then rapidly clears from the body. Licensed to Steba Biotech. This photodynamic therapy is currently in phase I/II clinical trials as second line therapy for prostate cancer patients who had had failed radiation therapy.
Source: Van Nadel. Weizmann Institute’s Yeda has plenty of innovative drugs in the pipeline. (24 September 2006) [FullText][Cached Version]
Labels: Weizmann Institute
0 Comments:
Post a Comment
<< Home